Although a phase II clinical trial in untreated metastatic PDAC patients could not demonstrate significant clinical efficacy of the combination of gemcitabine and trametinib [17], another study in NSCLC with selumetinib as a MEK inhibitor demonstrated significant clinical benefits in combination with docetaxel, indicating the possibility of some synergy potential of MEK inhibitors with taxanes compared with gemcitabine [18]. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.